As costs for cancer care continue to rise, Pontchartrain Cancer Center does benefit and cost analyses for all patients before they start therapy and also takes into account any social needs they might have, said Kathy W. Oubre, MS, chief operating officer at Pontchartrain Cancer Center.
As costs for cancer care continue to rise, Pontchartrain Cancer Center does benefit and cost analyses for all patients before they start therapy and also takes into account any social needs they might have, said Kathy W. Oubre, MS, chief operating officer at Pontchartrain Cancer Center.
Transcript
How are you providing financial counseling assistance to the patients at Pontchartrain Cancer Center?
So, every patient that we see prior to the initiation of therapy, we do a benefit analysis as well as a cost analysis for them of their co-pays, their deductible, and everything. And anything that is $50 or more triggers our financial assistance people to then go in a look for assistance for those people to be able to afford their therapy.
But going back to my more rural market, we’ve now changed that to look for financial assistance for everyone. Because $50 for 1 person might look very different an $50 for another person.
So, in addition to financial help, we’ve really started addressing the patient as a whole in addressing all of their social needs as well. So, we look for transportation, help with their electricity, rent—so, our program that was once just financial offerings we’ve increased it 10-fold over the last 18 months as costs continue to rise and rise for our patients.
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
In VERIFY, Rusfertide Spares Most Patients With PV a Phlebotomy for 32 Weeks, Improves QOL
June 3rd 2025Adding rusfertide to standard of care more than doubled the share of patients with polycythemia vera (PV) who did not meet criteria for a phlebotomy, according to data from the VERIFY trial.
Read More